1. Which of the following treatment regimens was most effective in prolonging long-term overall survival at 7.5 year follow-up when used for first-line treatment of metastatic melanoma in the phase 3 CheckMate 067 clinical trial?

2. BN is a 43-year-old male with BRAF V600E-mutated stage IV melanoma of unknown primary, with oligometastatic disease in the axilla that was successfully resected 8 weeks ago. He now has no evidence of disease and is treatment-naive. He presents to the medical oncology clinic for consideration of adjuvant therapy. Which of the following is the only approved treatment modality for resected stage IV melanoma with an NCCN Category 1 recommendation and would be the most appropriate choice of therapy?

3. Which of the following regimens demonstrated extended progression-free survival and twice the incidence of grade 3 or 4 treatment-related adverse events when compared with nivolumab monotherapy in patients with untreated metastatic melanoma in the RELATIVITY-047 trial?

4. HU is a 59-year-old male with metastatic melanoma on cycle 3 of nivolumab + relatlimab. He presents with moderate-to-severe fatigue which is not attributable to any activity. Which of the following is an immune-related adverse event which should be tested for as a common cause of fatigue during ICI therapy and is generally considered to be permanent?

5. LE is a 75-year-old female with BRAF wild-type metastatic melanoma who was hospitalized and diagnosed with grade 3 hepatitis following cycle 5 of pembrolizumab. She was initiated on prednisone 1 mg/kg once daily, which improved her transaminase levels to grade 1 over the course of the next several weeks. She presents to clinic for initiation of a steroid taper. Per national consensus guidelines, which of the following is the minimum threshold for consideration of prophylaxis against Pneumocystis jirovecii (PJP) during steroid use for an irAE?

« Return to Activity